Nanotechnology platform sensitises cancer to immunotherapy
A new pre-clinical study has utilised nanoparticles to attach immune-activating molecules to cancer cells.
List view / Grid view
A new pre-clinical study has utilised nanoparticles to attach immune-activating molecules to cancer cells.
NIH researchers who intravenously delivered a cancer vaccine to mice report that it increased the number of T cells able to combat tumours.
UPF and John Hopkins scientists have discovered how cancer cells exposed to high viscosity environments change their movements to improve their invasiveness and favour metastases.
Spanish researchers have discovered that vitamin C may hold the key to improving the efficacy of dendritic cell-derived anticancer therapies.
In the production of RNA, researchers in Spain and Denmark have found a method for attacking cancer cells.
US researchers have found that G protein-coupled receptors function in a way not previously known, which suggests untapped potential.
Scientists have developed a new method to study the proteins released by cells, which could lead to the development of new tools to track diseases including cancer.
Dr Larysa Baraban, physicist at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) is researching a chip that should ultimately make it possible to develop personalised cancer immunotherapies.
Researchers have eradicated malignant tumours in mice by combining an immunotherapy agent with a molecular delivery system that targets tumour acidity.
The team from Hangzhou Dianzi University developed a three-dimensional-stacked multi-stage inertial microfluidic sort chip to enrich and separate CTCs.
Trinity College Dublin has developed a new technique that accurately determines the state of macrophages.
This exclusive ebook takes an in-depth look at recent developments in the field of cancer immunotherapy, with expert interviews exploring how researchers are advancing next-generation cell therapies into the clinic.
Researchers at the University of Arizona Health Sciences found that CD4 plays an active role in regulating T-cell receptor signalling.
Researchers have discovered a protein, Ait1, that is responsible for controlling cell growth in yeasts. Since humans and yeasts have remarkably similar cellular mechanisms, teasing out the differences presents drug developers with new target.
Researchers in Japan have succeeded in inhibiting cancer cell growth using pyrrolizidine alkaloid, a component of plant origin previously thought to be too toxic to administer.